Your browser doesn't support javascript.
loading
Identification and validation of a novel panel of Plasmodium knowlesi biomarkers of serological exposure.
Herman, Lou S; Fornace, Kimberly; Phelan, Jody; Grigg, Matthew J; Anstey, Nicholas M; William, Timothy; Moon, Robert W; Blackman, Michael J; Drakeley, Chris J; Tetteh, Kevin K A.
Afiliação
  • Herman LS; Department Immunology and Infection, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Fornace K; Department Immunology and Infection, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Phelan J; Department Immunology and Infection, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Grigg MJ; Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia.
  • Anstey NM; Infectious Diseases Society Sabah-Menzies School of Health Research Clinical Research Unit, Kota Kinabalu, Sabah, Malaysia.
  • William T; Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia.
  • Moon RW; Infectious Diseases Society Sabah-Menzies School of Health Research Clinical Research Unit, Kota Kinabalu, Sabah, Malaysia.
  • Blackman MJ; Infectious Diseases Society Sabah-Menzies School of Health Research Clinical Research Unit, Kota Kinabalu, Sabah, Malaysia.
  • Drakeley CJ; Clinical Research Centre, Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysia.
  • Tetteh KKA; Jesselton Medical Centre, Kota Kinabalu, Sabah, Malaysia.
PLoS Negl Trop Dis ; 12(6): e0006457, 2018 06.
Article em En | MEDLINE | ID: mdl-29902183
ABSTRACT

BACKGROUND:

Plasmodium knowlesi is the most common cause of malaria in Malaysian Borneo, with reporting limited to clinical cases presenting to health facilities and scarce data on the true extent of transmission. Serological estimations of transmission have been used with other malaria species to garner information about epidemiological patterns. However, there are a distinct lack of suitable serosurveillance tools for this neglected disease. METHODOLOGY/PRINCIPAL

FINDINGS:

Using in silico tools, we designed and expressed four novel P. knowlesi protein products to address the distinct lack of suitable serosurveillance tools PkSERA3 antigens 1 and 2, PkSSP2/TRAP and PkTSERA2 antigen 1. Antibody prevalence to these antigens was determined by ELISA for three time-points post-treatment from a hospital-based clinical treatment trial in Sabah, East Malaysia (n = 97 individuals; 241 total samples for all time points). Higher responses were observed for the PkSERA3 antigen 2 (67%, 65/97) across all time-points (day 0 36.9% 34/92; day 7 63.8% 46/72; day 28 58.4% 45/77) with significant differences between the clinical cases and controls (n = 55, mean plus 3 SD) (day 0 p<0.0001; day 7 p<0.0001; day 28 p<0.0001). Using boosted regression trees, we developed models to classify P. knowlesi exposure (cross-validated AUC 88.9%; IQR 86.1-91.3%) and identified the most predictive antibody responses. CONCLUSIONS/

SIGNIFICANCE:

The PkSERA3 antigen 2 had the highest relative variable importance in all models. Further validation of these antigens is underway to determine the specificity of these tools in the context of multi-species infections at the population level.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Antiprotozoários / Plasmodium knowlesi / Malária / Antígenos de Protozoários Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Antiprotozoários / Plasmodium knowlesi / Malária / Antígenos de Protozoários Idioma: En Ano de publicação: 2018 Tipo de documento: Article